BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35772960)

  • 1.
    Zhou R; Choi H; Cao J; Pantel A; Gupta M; Lee HS; Mankoff D
    J Nucl Med; 2023 Jan; 64(1):131-136. PubMed ID: 35772960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Zhou R; Pantel AR; Li S; Lieberman BP; Ploessl K; Choi H; Blankemeyer E; Lee H; Kung HF; Mach RH; Mankoff DA
    Cancer Res; 2017 Mar; 77(6):1476-1484. PubMed ID: 28202527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic Modeling of
    Viswanath V; Zhou R; Lee H; Li S; Cragin A; Doot RK; Mankoff DA; Pantel AR
    J Nucl Med; 2021 Aug; 62(8):1154-1162. PubMed ID: 33277391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
    Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
    J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer.
    Grinde MT; Hilmarsdottir B; Tunset HM; Henriksen IM; Kim J; Haugen MH; Rye MB; Mælandsmo GM; Moestue SA
    Breast Cancer Res; 2019 May; 21(1):61. PubMed ID: 31088535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Tracer
    Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
    Theranostics; 2017; 7(7):2048-2064. PubMed ID: 28656060
    [No Abstract]   [Full Text] [Related]  

  • 9. Fasting Enhances the Contrast of Bone Metastatic Lesions in
    Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468238
    [No Abstract]   [Full Text] [Related]  

  • 10. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
    Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
    PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional distribution and kinetics of [18F]fluciclovine (anti-[18F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer.
    Sörensen J; Owenius R; Lax M; Johansson S
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):394-402. PubMed ID: 23208700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Clinical Trial of
    Ulaner GA; Goldman DA; Corben A; Lyashchenko SK; Gönen M; Lewis JS; Dickler M
    J Nucl Med; 2017 Jul; 58(7):1037-1042. PubMed ID: 27856630
    [No Abstract]   [Full Text] [Related]  

  • 13. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.
    Lieberman BP; Ploessl K; Wang L; Qu W; Zha Z; Wise DR; Chodosh LA; Belka G; Thompson CB; Kung HF
    J Nucl Med; 2011 Dec; 52(12):1947-55. PubMed ID: 22095958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive
    Henry KE; Dilling TR; Abdel-Atti D; Edwards KJ; Evans MJ; Lewis JS
    J Nucl Med; 2018 Jan; 59(1):51-57. PubMed ID: 28848040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterising
    Scott NP; Teoh EJ; Flight H; Jones BE; Niederer J; Mustata L; MacLean GM; Roy PG; Remoundos DD; Snell C; Liu C; Gleeson FV; Harris AL; Lord SR; McGowan DR
    Br J Cancer; 2022 Mar; 126(4):598-605. PubMed ID: 34795409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
    Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
    Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of
    Jani AB; Schreibmann E; Rossi PJ; Shelton J; Godette K; Nieh P; Master VA; Kucuk O; Goodman M; Halkar R; Cooper S; Chen Z; Schuster DM
    J Nucl Med; 2017 Mar; 58(3):412-418. PubMed ID: 27609792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for
    Kim EH; Siegel BA; Teoh EJ; Andriole GL;
    Urol Oncol; 2021 Jun; 39(6):365.e9-365.e16. PubMed ID: 33160848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyruvate anaplerosis is a mechanism of resistance to pharmacological glutaminase inhibition in triple-receptor negative breast cancer.
    Singleton DC; Dechaume AL; Murray PM; Katt WP; Baguley BC; Leung EY
    BMC Cancer; 2020 May; 20(1):470. PubMed ID: 32450839
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Michaud L; Beattie BJ; Akhurst T; Dunphy M; Zanzonico P; Finn R; Mauguen A; Schöder H; Weber WA; Lassman AB; Blasberg R
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1353-1367. PubMed ID: 31418054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.